Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Background Up to half of patients with infective endocarditis (IE) require cardiac surgery. Although anaemia is common, its precise prevalence, transfusion practices and impact on outcomes in ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics ...

Kidney disease is a silent global crisis, affecting millions, with women over 40 facing a heightened risk due to hormonal ...

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan ...

Chronic kidney disease, or CKD, is a health condition where the kidneys slowly stop working well over time. It is often called a silent disease because many people don’t feel sick in the early stages.

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused ...